Smith & Nephew Stock Forecast, Price & News

-0.14 (-0.35 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume503,785 shs
Average Volume554,831 shs
Market Capitalization$17.37 billion
P/E Ratio30.63
Dividend Yield2.20%
30 days | 90 days | 365 days | Advanced Chart
Receive SNN News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

Smith & Nephew logo

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.39 out of 5 stars

Medical Sector

277th out of 1,309 stocks

Surgical Appliances & Supplies Industry

6th out of 25 stocks

Analyst Opinion: 3.4Community Rank: 3.6Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Smith & Nephew (NYSE:SNN) Frequently Asked Questions

Is Smith & Nephew a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Smith & Nephew stock.
View analyst ratings for Smith & Nephew
or view top-rated stocks.

What stocks does MarketBeat like better than Smith & Nephew?

Wall Street analysts have given Smith & Nephew a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Smith & Nephew wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Smith & Nephew?

Smith & Nephew saw a drop in short interest in July. As of July 15th, there was short interest totaling 511,200 shares, a drop of 23.6% from the June 30th total of 668,900 shares. Based on an average daily volume of 645,800 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.1% of the company's shares are sold short.
View Smith & Nephew's Short Interest

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) issued its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.59.
View Smith & Nephew's earnings history

How has Smith & Nephew's stock been impacted by COVID-19?

Smith & Nephew's stock was trading at $38.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SNN stock has increased by 2.0% and is now trading at $39.51.
View which stocks have been most impacted by COVID-19

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a semi-annual dividend on Monday, February 22nd. Investors of record on Tuesday, April 6th will be given a dividend of $0.462 per share on Wednesday, May 12th. This represents a dividend yield of 1.8%. The ex-dividend date is Monday, April 5th. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.28.
View Smith & Nephew's dividend history

Is Smith & Nephew a good dividend stock?

Smith & Nephew pays an annual dividend of $0.90 per share and currently has a dividend yield of 2.20%. Smith & Nephew does not yet have a strong track record of dividend growth. The dividend payout ratio of Smith & Nephew is 69.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Smith & Nephew will have a dividend payout ratio of 43.27% next year. This indicates that Smith & Nephew will be able to sustain or increase its dividend.
View Smith & Nephew's dividend history.

What price target have analysts set for SNN?

8 brokers have issued twelve-month target prices for Smith & Nephew's shares. Their forecasts range from $46.50 to $55.00. On average, they anticipate Smith & Nephew's stock price to reach $50.75 in the next year. This suggests a possible upside of 28.4% from the stock's current price.
View analysts' price targets for Smith & Nephew
or view top-rated stocks among Wall Street analysts.

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the following people:
  • Mr. Roland D. Diggelmann, CEO & Director (Age 54, Pay $1.7M)
  • Ms. Anne-Francoise Nesmes, CFO & Exec. Director (Age 49, Pay $799.64k)
  • Mr. Mark Gladwell, Pres of Global Operations & Global Bus. Services (Age 46)
  • Mr. Andrew Swift, VP of Investor Relations
  • Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 48)
  • Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
  • Ms. Elga Lohler, Chief HR Officer (Age 53)
  • Mr. Philip G. Cowdy, Chief Bus. Devel. & Corp. Affairs Officer (Age 54)
  • Mr. Bradley Cannon, Pres of Sports Medicine & ENT (Age 53)
  • Dr. Vasant Padmanabhan, Pres of R&D (Age 54)

Who are some of Smith & Nephew's key competitors?

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cambiar Investors LLC (0.40%), Henry James International Management Inc. (0.04%), Manning & Napier Group LLC (0.01%), Reilly Financial Advisors LLC (0.01%), Canvas Wealth Advisors LLC (0.01%) and Eagle Global Advisors LLC (0.01%).

Which institutional investors are selling Smith & Nephew stock?

SNN stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Advisor Group Holdings Inc., Raymond James Trust N.A., Atlas Capital Advisors LLC, Baldwin Brothers Inc. MA, Mckinley Capital Management LLC Delaware, and Fisher Asset Management LLC.

Which institutional investors are buying Smith & Nephew stock?

SNN stock was purchased by a variety of institutional investors in the last quarter, including Clean Yield Group, Henry James International Management Inc., Brinker Capital Investments LLC, Manning & Napier Group LLC, DAVENPORT & Co LLC, Veriti Management LLC, Eagle Global Advisors LLC, and Ridgewood Investments LLC.

How do I buy shares of Smith & Nephew?

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $39.51.

How much money does Smith & Nephew make?

Smith & Nephew has a market capitalization of $17.37 billion and generates $4.56 billion in revenue each year. The medical equipment provider earns $448 million in net income (profit) each year or $1.29 on an earnings per share basis.

How many employees does Smith & Nephew have?

Smith & Nephew employs 18,000 workers across the globe.

When was Smith & Nephew founded?

Smith & Nephew was founded in 1856.

What is Smith & Nephew's official website?

The official website for Smith & Nephew is www.smith-nephew.com.

Where are Smith & Nephew's headquarters?

Smith & Nephew is headquartered at BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider can be reached via phone at 44-19-2347-7100 or via email at [email protected]

This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.